Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Profit After Tax (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Profit After Tax for 7 consecutive years, with -$23.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 52.59% to -$23.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$149.3 million, a 28.99% increase, with the full-year FY2025 number at -$149.3 million, up 28.99% from a year prior.
  • Profit After Tax was -$23.6 million for Q4 2025 at Pliant Therapeutics, up from -$26.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$22.8 million in Q2 2021 to a low of -$57.8 million in Q3 2024.
  • A 5-year average of -$37.1 million and a median of -$36.3 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: tumbled 307.24% in 2021, then soared 54.47% in 2025.
  • Pliant Therapeutics' Profit After Tax stood at -$24.5 million in 2021, then crashed by 42.92% to -$35.1 million in 2022, then dropped by 17.25% to -$41.1 million in 2023, then fell by 20.98% to -$49.7 million in 2024, then skyrocketed by 52.59% to -$23.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Profit After Tax are -$23.6 million (Q4 2025), -$26.3 million (Q3 2025), and -$43.3 million (Q2 2025).